# Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

> **NCT00016055** · PHASE1 · UNKNOWN · sponsor: **St. Luke's Medical Center** · enrollment: 18 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** lymphokine-activated killer cells
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00016055
- **Lead sponsor:** St. Luke's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00016055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00016055, "Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00016055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*